Table 2 Univariate analysis comparing patients with or without EBV infection within 365 days post-HSCT in the derivation cohort

Patients age, median(range)

26 (1–64)

29.5 (1–66)

0.339

Donors age, median(range)

37.5 (9–65)

42 (9–65)

0.012

Patients gender, n(%)

0.060

 Male

117

35

 Female

84

13

Donors gender, n(%)

0.178

 Male

153

32

 Female

48

16

ABO type, n(%)

0.016

 Match

95

32

 Mismatch

106

16

Donor-recipient relationship, n(%)

0.336

 Patrents to children

118

33

 Children to parents

46

10

 Sibling

37

5

Donor-recipient gender, n(%)

0.004

 Female to male

25

14

 Others

176

34

Stem cell source, n(%)

0.106

 BM + PB

34

13

 PB

167

35

Serological EBV status of patients and donors, n(%)

0.588

 P−D−

1

0

 P−D + 

8

0

 P + D−

8

1

 P + D + 

184

47

HLA mismatch, n(%)

0.405

 1

14

1

 2

22

7

 3

165

40

aGVHD, n(%)

0.331

 aGVHD−

123

27

 aGVHD grade 1–2

68

16

 aGVHD grade 3–4

10

5

Count of grafts components/kg, median(range)

 MNC (10⁸/kg)

9.29 (5.01–20.25)

10.27 (5.3–19.15)

0.028

 CD34 (10⁶/kg)

3.42 (0.67–17.64)

3.39 (1.28–13.09)

0.575

 Lym (10⁶/kg)

370.30 (91.28–960.46)

385.54 (151.18–640.10)

0.666

 CD14 (10⁶/kg)

157.82 (55.11–348.05)

155.32 (84.31–360.26)

0.369

 CD3 (10⁶/kg)

255.03 (64.62–650.48)

254.01 (74.32–496.17)

0.585

 CD4 (10⁶/kg)

139.65 (38.39–414.48)

141.61 (43.69–331.41)

0.846

 CD8 (10⁶/kg)

89.05 (20.17–277.85)

84.95 (24.87–206.48)

0.138

 NK (10⁶/kg)

35.96 (6.09–183.20)

30.28 (7.27–107.07)

0.347